Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | F3 | P13726 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765443 | 0.90 | ELANE (0.39) | DGAT2NTRK1IRAK4NTRK3HDAC6 | |
| SCHEMBL30765889 | 0.88 | ELANE (0.38) | DGAT2NTRK1NTRK3F3 | |
| SCHEMBL30765466 | 0.87 | DGAT2 (0.47) | DGAT2F3 | |
| SCHEMBL30765930 | 0.85 | IRAK4 (0.44) | NTRK1IRAK4HDAC1MAPK1 | |
| SCHEMBL30765732 | 0.80 | NTRK1 (0.40) | DGAT2NTRK1NTRK3HDAC1HDAC8 | |
| SCHEMBL30766050 | 0.80 | ELANE (0.41) | NTRK1NTRK3F3F2 | |
| SCHEMBL23511258 | 0.80 | F2 (0.51) | F2 | |
| SCHEMBL30765840 | 0.80 | NAMPT (0.38) | DGAT2NTRK1IRAK4NTRK3F3 | |
| SCHEMBL31558568 | 0.80 | NTRK1 (0.45) | NTRK1NTRK3HDAC1F3 | |
| SCHEMBL30765478 | 0.78 | CASP1 (0.41) | NTRK1NTRK3HDAC1F3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |